Friday, December 5, 2008
Afternoon Symposia: 12:30 p.m. - 4:30 p.m.
- The Real Deal With CML: Case- and Dialogue-Based Education Designed to Facilitate Integration of New Agents and Guidelines Into Clinical Practice
- Overcoming Resistance in CML: Contemporary Disease Monitoring Practices
- Thromboembolism in Cancer Patients: A Cogent Approach to Risk Assessment, Prevention, and Treatment
- Second Opinion: An Interactive Case-Based Discussion on the Management of Non-Hodgkin Lymphomas
- High-Risk AML: Molecular Biology, Treatment, Future Directions
- 50 Years of Enormous Progress in Hairy Cell Leukemia: A Celebration of Clinical Research With Remaining Unanswered Questions
- The Hematology Circle: Optimizing Epigenetic Therapy to Improve Outcomes
- Treating AML/MDS in the Elderly: New Solutions for a Long-Standing Problem
- Emerging Standards of Care: Bringing Advances in Myeloma Therapy Into the Real World
- Cellular Therapy: Stem Cell Transplantations From Matched Related and Unrelated Donors
- Solving the Challenges of Hematologic Malignancies Through Translational Science
The Real Deal With CML: Case- and Dialogue-Based Education Designed to Facilitate Integration of New Agents and Guidelines Into Clinical Practice
This program is sponsored by the Veritas Institute for Medical Education and supported by Bristol Myers Squibb Company.
| Location: | San Francisco Marriott – Yerba Buena Ballroom, Salon 7 and 8 | |
| Speakers: | Neil Shah, MD, PhD, University of California – San Francisco, San Francisco, CA
|
|
| John M. Goldman, DM, Imperial College School of Medicine, Hammersmith Hospital, London, United Kingdom
|
||
| Timothy Hughes, MD, Institute of Medical and Veterinary Science, Adelaide, Australia
|
||
| Moshe Talpaz, MD, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
|
||
| Michael Mauro, MD, Oregon Health and Science University, Portland, OR |
In the development of new treatments for patients with chronic myelogenous leukemia (CML), progress from the bench to bedside has been rapid. Although hematologists and oncologists appreciate the efficacy of treatment options in patients with CML, there remain a number of key questions: What is the appropriate method for monitoring response to therapy? Which is the more important goal: complete cytogenetic response or major molecular response? Does time to response matter? Under what circumstances should a change in therapy be considered? This symposium will lay the foundation for understanding the rationale behind current recommendations in diagnosis, treatment, and management of CML. Employing evidence-based, point-counterpoint-style dialogues and interactive cases, the symposium will be a forum for oncologists and hematologists to examine and discuss these current key questions regarding the mechanisms of disease and drug resistance, the usefulness of frequent molecular testing, and new treatment regimens based on recent clinical trials and emerging data.
For more information, contact:
Linda Ritter, Veritas Institute for Medical Education
Phone: 201-727-1115, ext. 2353
Fax: 201-727-1529
Overcoming Resistance in CML: Contemporary Disease Monitoring Practices
This program is sponsored by SciMed, LLC, and supported by ChemGenex Pharmaceuticals.
| Location: | Hilton San Francisco – Imperial Ballroom A and B | |
| Speakers: | Jane F. Apperley, MD, Imperial College School of Medicine, Hammersmith Hospital, London, United Kingdom
|
|
| Alfonso Quintas-Cardama, MD, The University of Texas M. D. Anderson Cancer Center, Houston, TX
|
||
| Andreas Hochhaus, MD, Fakultät Mannheim, University of Heidelberg, Mannheim, Germany
|
||
| Franck Emmanuel Nicolini, MD, PhD, Hôpital Edouard Herriot, Lyon, France
|
||
| Luke Akard, MD, Indiana Bone and Marrow Transplantation, Beach Grove, IN |
Proper CML management is continually evolving and brings with it new challenges that must be overcome to ensure optimal therapeutic outcomes. Monitoring methods used to assess response to therapy are critical to guide treatment strategies, especially for those patients who are resistant, intolerant, or have a suboptimal response to tyrosine kinase inhibitors. Given this rapidly changing environment, it is crucial that hematologist/oncologists and medical oncologists be kept abreast of new advances in CML. The proposed continuing medical education activity will highlight proper monitoring techniques as well as current and emerging agents for CML treatment.
For more information, contact:
David Moore, SciMed, LLC
Phone: 646-416-5180
Fax: 646-873-5570
Thromboembolism in Cancer Patients: A Cogent Approach to Risk Assessment, Prevention, and Treatment
This program is sponsored by the Boston University School of Medicine and supported by Eisai, Inc.
| Location: | Hilton San Francisco – Continental Ballroom 5 | |
| Speakers: | Gary H. Lyman, MD, Duke University Medical Center, Duke Comprehensive Cancer Center, Duke Center for Clinical Health Policy Research, Durham, NC
|
|
| Alok A. Khorana, MD, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY
|
||
| Michael M. Millenson, MD, Fox Chase Cancer Center, Philadelphia, PA |
Combining didactic and interactive components, this symposium will provide attendees with an understanding of venous thromboembolism and its relationship to cancer, discuss risk assessment and stratification, review available antithrombotic agents, and detail the latest recommendations from the National Comprehensive Cancer Network and the American Society of Clinical Oncology for the prevention and treatment of this life-threatening condition. Case studies with Audience Response System (ARS) questions will help attendees apply recommendations and therapeutic options to clinical practice and allow for audience participation, as will a question-and-answer session with the expert speakers.
For more information, contact:
Gina Domanico, Haymarket Medical Education
Phone: 201-799-4815
Fax: 201-799-4820
Second Opinion: An Interactive Case-Based Discussion on the Management of Non-Hodgkin Lymphomas
This program is sponsored by Research To Practice and supported by Genentech, Inc.
| Location: | Moscone Center South, Esplanade Level, Room 307/309 | |
| Speakers: | Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute, Nashville, TN
|
|
| Stephanie A. Gregory, MD, Rush University Medical Center, Chicago, IL
|
||
John P. Leonard, MD, New York Presbyterian Hospital, New York, NY
|
||
David G. Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA
|
||
Mitchell R. Smith, MD, PhD, Fox Chase Cancer Center, Philadelphia, PA
|
||
| Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY |
This unique live event will employ a dynamic and engaging format to deliver relevant and important educational perspectives to clinician learners. The meeting will be designed to center on six actual, but de-identified, case presentations from the practices of community-based medical oncologists and hematologists from across the United States. Prior to the meeting, Research To Practice will videotape six clinicians describing a specific patient's case history, including the disease presentation, the management approaches suggested, and the treatment decisions that were ultimately made.
For more information,
contact:
Courtney Lohmann, Research To Practice
Phone: 305-400-7306
Fax: 800-960-2944
High-Risk AML: Molecular Biology, Treatment, Future Directions
This program is sponsored by the Educational Concepts Group, Inc., and supported by Genzyme Corporation.
| Location: | Moscone Center West, Level 2, Room 2009/2011/2022/2024 | |
| Speakers: | Hagop M. Kantarjian, MD, The University of Texas M. D. Anderson Cancer Center, Houston, TX
|
|
| Hartmut Döhner, MD, University of Ulm, Ulm, Germany
|
||
| Jerald P. Radich, MD, Fred Hutchinson Cancer Research Center, Seattle, WA
|
||
| Wendy Stock, MD, University of Chicago, Chicago, IL
|
||
| Richard Stone, MD, Harvard Medical School, Boston, MA
|
||
| Gail Roboz, MD, Weill Cornell Medical College, New York, NY
|
||
| Daniel Weisdorf, MD, University of Minnesota, Minneapolis, MN |
This symposium is an innovative educational program that will include a panel of seven experts. This live, independent educational program will provide hematologists and other allied health-care professionals who treat patients with AML with pertinent information about management issues and treatment strategies through multi-topic lectures, discussions, and panel debates. In addition, the symposium will utilize case presentations designed specifically to reinforce key learning objectives. To maximize audience participation, a Web-based audience response system (ARS) will be utilized. The Web-based ARS allows for all of the features traditional ARS offers, such as polling, pre- and post-test, and evaluation survey, as well as splicing and comparing of data. In addition, the Web-based ARS will offer attendees the opportunity to text the moderator questions in real time. The moderator will receive the questions to review, edit, and approve for screen display. All questions will be captured and exported into Excel and summarized in a post-meeting report.
For more information, contact:
Tina Stacy, Educational Concepts Group, Inc
Phone: 770-933-1684
Fax: 770-933-1692
50 Years of Enormous Progress in Hairy Cell Leukemia: A Celebration of Clinical Research With Remaining Unanswered Questions
This program is sponsored by The Ohio State University Center for Continuing Medical Education and supported by Hospira, Inc.
| Location: | Moscone Center West, Level 3, Room 3000/3002/3004 | |
| Speakers: | John Cawley, MD, PhD, University of Liverpool, Liverpool, United Kingdom |
|
| Alan Saven, MD, Scripps Clinic and Research Foundation, Ida M. and Cecil Green Cancer Center, La Jolla, CA |
||
Francesco Lauria, MD, University of Siena, Siena, Italy |
||
| Michael Grever, MD, The Ohio State University, Columbus, OH |
||
| Daniel Catovsky, MD, Professor, Institute of Cancer Research, London, UK |
||
| Deborah Thomas, MD, Assistant Professor, University of Texas, M. D. Anderson Cancer Center, Houston, Texas |
||
| Pier Luigi Zinzani, MD, Associate Professor, Universita Di Bologna, Bologna, Italy |
A panel of international experts in this disease has met over the past year with the purpose of increasing knowledge of the current state of the diagnosis and management of this disease. The proposed agenda includes case-based patient presentations to illustrate important points for the practicing hematologist.
For more information, contact:
Nancy Jones, The Ohio State University Comprehensive Cancer Center
Phone: 614-293-3688
Fax: 614-293-3305
The Hematology Circle: Optimizing Epigenetic Therapy to Improve Outcomes
This program is sponsored by OptumHealth Education and supported by Merck and Co., Inc.
| Location: | San Francisco Marriott – Yerba Buena Ballroom, Salon 9 | |
| Speakers: | Ashraf Z. Badros, MD, University of Maryland, Greenebaum Cancer Center, Baltimore, MD
|
|
| Francine M. Foss, MD, Yale University, Yale Cancer Center, New Haven, CT
|
||
| Elihu E. Estey, MD, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA
|
||
| Jorge Eduardo Cortes, MD, The University of Texas M. D. Anderson Cancer Center, Houston, TX |
Following a short didactic presentation on the relationship between the pathogenesis of hematologic malignancies and epigenetic abnormalities and the biologic rationale for combining therapies, the case-based discussion will highlight how this information can be incorporated into treatments to maximize outcomes. The activity will focus on disease states, rather than individual diseases, because of the relationship between certain diseases and their underlying biologic natural history and treatment.
For more information, contact:
Jan Gbur, OptumHealth Education
Phone: 973-647-6911
Treating AML/MDS in the Elderly: New Solutions for a Long-Standing Problem
This program is sponsored by Northwestern University Feinberg School of Medicine and supported by MGI Pharma, Inc, Vion Pharmaceuticals, Inc, and the Geriatric Oncology Consortium.
| Location: | Moscone Center West, Level 3, Room 3009/3011/3022/3024 | |
| Speakers: | Jacob Rowe, MD, Northwestern University, Chicago, IL
|
|
| Judy Karp, MD, The Johns Hopkins University, Baltimore, MD
|
||
| Bob Löwenberg, MD, Erasmus University Medical Center, Rotterdam, Netherlands
|
||
| Rainer Storb, MD, Fred Hutchinson Cancer Research Center, Seattle, WA
|
||
| Christopher Bredeson, MD, Medical College of Wisconsin, Milwaukee, WI
|
||
| Gary Schiller, MD, University of California – Los Angeles, Los Angeles, CA
|
||
| Maria Baer, MD, University of Maryland, Greenebaum Cancer Center, Baltimore, MD |
Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are complicated diseases with complex genotypes. A great deal of information is being discovered about the mutations in AML and genetic alterations in MDS and how they affect prognosis. Treatment of AML and MDS depends on the type of DNA change and the availability of targeted agents. For both of these diseases, there are a number of novel agents being developed that have shown success in preliminary studies. Physicians need to be made aware of the current developments in the biology and treatment of AML and MDS and how these agents may be used in treating this cancer.
For more information, contact:
Robin Simak, Hemedicus
Phone: 201-666-4700
Fax: 201-666-4747
Emerging Standards of Care: Bringing Advances in Myeloma Therapy Into the Real World
This program is sponsored by The Center for Biomedical Continuing Education and supported by Millennium Pharmaceuticals, Inc.
| Location: | Hilton San Francisco - Grand Ballroom, Salon B | |
| Speakers: | Sergio Giralt, MD, The University of Texas M. D. Anderson Cancer Center, Houston, TX
|
|
| Michele Cavo, MD, Bologna University School of Medicine, Bologna, Italy
|
||
| Meletios A. Dimopoulos, MD, University of Athens School of Medicine, Athens, Greece
|
||
| Mario Boccadoro, MD, University of Turin, Turin, Italy
|
||
| Jeffrey Zonder, MD, Barbara Ann Karmanos Cancer Institute, Detroit, MI
|
||
| Shaji Kumar, MD, Mayo Clinic, Rochester, MN
|
||
| Jonathan Kaufman, MD, Emory University School of Medicine, Atlanta, GA
|
||
| Hakan Kaya, MD, University of Washington School of Medicine, Spokane, WA
|
||
| Choon-Kee Lee, MD, University of Colorado Health Sciences Center, Denver, CO
|
||
| Magda Migkou, MD, University of Athens, School of Medicine, Athens, Greece
|
||
| Elena Zamagni, MD, University of Bologna, Bologna, Italy |
Five multiple myeloma specialists from various community-level institutions in different geographic regions will be featured discussing cases specific to their practices. These cases will be selected to analyze the similarities and differences in treatment selection and management of treatment-related complications associated with multiple myeloma in different regions of the United States and Europe. The specialists will be videotaped prior to the live symposium. They will also attend the symposium to participate in the question-and-answer sessions.
For more information, contact:
Shawn Shinn, The Center for Biomedical Continuing Education
Phone: 972-692-2078
Fax: 214-260-0509
Cellular Therapy: Stem Cell Transplantations From Matched Related and Unrelated Donors
This program is sponsored by Postgraduate Institute for Medicine and supported by Miltenyi Biotec GmbH.
| Location: | Moscone Center West, Level 2, Room 2000/2002/2004 | |
| Speakers: | Ralf G. Meyer, MD, Johannes Gutenberg University, Mainz, Germany
|
|
| Jeffrey S. Miller, MD, University of Minnesota, Minneapolis, MN
|
||
| Matthias Edinger, MD, University Hospital of Regensburg, Regensburg, Germany
|
||
| Tobias Feuchtinger, MD, University Children's Hospital, Eberhard-Karls University, Tuebingen, Germany |
Adoptive cellular therapy has found its way into the treatment of hematologic malignancies, solid tumors, autoimmune diseases, and viral diseases. Nevertheless, cellular therapy is still considered an experimental approach; currently, no standard treatment protocols exist and approaches are discussed controversially. This symposium will provide a platform for discussion of new advances in allogeneic stem cell transplantation from matched related and unrelated donors. New strategies for disease management in these settings using cellular therapy will be presented to the audience, including long-term outcomes from patients enrolled in clinical trials. Prospectively designed protocols enabled by novel clinical-grade cell separation tools will also be presented.
For more information, contact:
Farzad Bayati, Malachite Management, Inc.
Phone: 604-874-4004
Fax: 604-874-4378
Solving the Challenges of Hematologic Malignancies Through Translational Science
This program is sponsored by Imedex, LLC, and supported by Novartis.
| Location: | Moscone Center South, Exhibit Level, Room 104 | |
| Speakers: | Jonathan Licht, MD, Northwestern University, Chicago, IL
|
|
| Owen O'Connor, MD, PhD, Columbia University, New York, NY
|
||
| H. Miles Prince, MD, Peter MacCallum Cancer Center, Melbourne, Australia
|
||
| Frank Giles, MD, University of Texas, San Antonio, TX
|
||
| Ruben Mesa, MD, Mayo Clinic, Rochester, MN |
This symposium is designed to discuss the novel therapeutic agents of hematologic malignancies that are being developed and evaluated in clinical trials. With ongoing research in the relationship of epigenetics and cancer, the development of targeted agents, such as histone deaceytlase inhibitors, has resulted in the expanded utilization of tyrosine kinase inhibitors. The format of this symposium is plenary lectures that will educate health-care professionals on the available data of these targeted agents to keep them abreast of the rapidly growing therapeutic options.
For more information, contact:
Elke Koscher, Imedex, LLC
Phone: 770-751-7332
Fax: 770-751-7334